All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Professor Michael Hallek is the Director of Clinic I for Internal Medicine and Associated Principle Investigator at the University Hospital Cologne, Cologne, DE, and the Director of the Center of Integrated Oncology (CIO) in Aachen, Bonn, Cologne, and Düsseldorf, DE.
Prof. Hallek obtained his medical degree from the Ludwig-Maximilians-Universität München, DE, in 1985 and was a Research Associate at the Dana Farber Cancer Institute and Harvard Medical School, Boston, US, from 1990–1992. He became a senior consultant at the Ludwig-Maximilians-Universität München, DE, between 1995−2003. His main research focus is chronic lymphocytic leukemia.
Positions of responsibility/awards:
Founder and Chairman of the German CLL Study Group since 1996